Literature DB >> 10705919

Immunotherapeutic approaches for the treatment of breast cancer.

K L Knutson1, K Schiffman, K Rinn, M L Disis.   

Abstract

The application of immunotherapeutic principles to the treatment and prevention of breast cancer is a relatively new undertaking. Although cytokine infusions, cancer vaccines, and T cell therapy have been extensively studied in solid tumors such as melanoma and renal cell carcinoma, the therapeutic efficacy of these approaches is not well explored in breast cancer. The recent definition of tumor-specific immunity in breast cancer patients and the identification of several breast cancer antigens has generated enthusiasm for the application of immune-based therapies to the treatment of breast malignancies. In general, immunotherapies can be considered either non-specific, such as a general immunomodulator (e.g., a cytokine), or tumor-specific (e.g., a vaccine that targets breast cancer tumor antigens). This review describes three major immunotherapeutic strategies that have the potential to enhance or generate an anti-breast cancer T cell immune response: (i) cytokine therapy; (ii) cancer vaccines; and (iii) T cell therapy, and explores how each strategy has been applied to the treatment of breast cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10705919     DOI: 10.1023/a:1018714300217

Source DB:  PubMed          Journal:  J Mammary Gland Biol Neoplasia        ISSN: 1083-3021            Impact factor:   2.673


  75 in total

1.  Immunization of metastatic breast cancer patients with CD80-modified breast cancer cells and GM-CSF.

Authors:  D D Schoof; J W Smith; M L Disis; P Brant-Zawadski; W Wood; T Doran; E Johnson; W J Urba
Journal:  Adv Exp Med Biol       Date:  1998       Impact factor: 2.622

2.  Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.

Authors:  J S Miller; J Tessmer-Tuck; B A Pierson; D Weisdorf; P McGlave; B R Blazar; E Katsanis; C Verfaillie; J Lebkowski; J Radford; L J Burns
Journal:  Biol Blood Marrow Transplant       Date:  1997-04       Impact factor: 5.742

3.  Immunotherapy with interleukin-2 and alpha-interferon after IL-2-activated hematopoietic stem cell transplantation for breast cancer.

Authors:  K R Meehan; B Arun; E A Gehan; B Berberian; V Sulica; E M Areman; A Mazumder; M E Lippman
Journal:  Bone Marrow Transplant       Date:  1999-04       Impact factor: 5.483

4.  Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity.

Authors:  S Y Shu; T Chou; K Sakai
Journal:  J Immunol       Date:  1989-07-15       Impact factor: 5.422

5.  Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial.

Authors:  A K Stewart; N J Lassam; I C Quirt; D J Bailey; L E Rotstein; M Krajden; S Dessureault; S Gallinger; D Cappe; Y Wan; C L Addison; R C Moen; J Gauldie; F L Graham
Journal:  Gene Ther       Date:  1999-03       Impact factor: 5.250

Review 6.  Cancer vaccines.

Authors:  T F Greten; E M Jaffee
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

Review 7.  Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer.

Authors:  H Tahara; M T Lotze
Journal:  Gene Ther       Date:  1995-03       Impact factor: 5.250

8.  Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.

Authors:  S L Topalian; D Solomon; F P Avis; A E Chang; D L Freerksen; W M Linehan; M T Lotze; C N Robertson; C A Seipp; P Simon
Journal:  J Clin Oncol       Date:  1988-05       Impact factor: 44.544

9.  Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial.

Authors:  R I Fisher; C A Coltman; J H Doroshow; A A Rayner; M J Hawkins; J W Mier; P Wiernik; J D McMannis; G R Weiss; K A Margolin
Journal:  Ann Intern Med       Date:  1988-04       Impact factor: 25.391

10.  Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing.

Authors:  G Kaplan; G Walsh; L S Guido; P Meyn; R A Burkhardt; R M Abalos; J Barker; P A Frindt; T T Fajardo; R Celona
Journal:  J Exp Med       Date:  1992-06-01       Impact factor: 14.307

View more
  1 in total

1.  CD73 participates in cellular multiresistance program and protects against TRAIL-induced apoptosis.

Authors:  Andrey Mikhailov; Alice Sokolovskaya; Gennady G Yegutkin; Hanne Amdahl; Anne West; Hideo Yagita; Riitta Lahesmaa; Linda F Thompson; Sirpa Jalkanen; Dmitry Blokhin; John E Eriksson
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.